Kenvue Inc. $KVUE Shares Sold by Keybank National Association OH

Keybank National Association OH decreased its position in shares of Kenvue Inc. (NYSE:KVUE) by 5.2% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,628,939 shares of the company’s stock after selling 256,023 shares during the quarter. Keybank National Association OH owned 0.24% of Kenvue worth $75,128,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. AlphaCore Capital LLC increased its holdings in Kenvue by 9.9% in the second quarter. AlphaCore Capital LLC now owns 5,287 shares of the company’s stock valued at $111,000 after buying an additional 476 shares in the last quarter. Empirical Finance LLC boosted its stake in shares of Kenvue by 1.8% during the 2nd quarter. Empirical Finance LLC now owns 28,309 shares of the company’s stock worth $593,000 after acquiring an additional 491 shares in the last quarter. Proffitt & Goodson Inc. grew its position in shares of Kenvue by 8.2% during the 2nd quarter. Proffitt & Goodson Inc. now owns 6,831 shares of the company’s stock valued at $143,000 after acquiring an additional 517 shares during the period. Altus Wealth Group LLC increased its stake in shares of Kenvue by 1.7% in the 2nd quarter. Altus Wealth Group LLC now owns 31,398 shares of the company’s stock valued at $657,000 after purchasing an additional 524 shares in the last quarter. Finally, J.W. Cole Advisors Inc. raised its holdings in Kenvue by 3.8% in the 2nd quarter. J.W. Cole Advisors Inc. now owns 15,488 shares of the company’s stock worth $324,000 after purchasing an additional 574 shares during the period. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Kenvue Trading Up 1.2%

Shares of KVUE stock opened at $17.41 on Friday. Kenvue Inc. has a fifty-two week low of $14.02 and a fifty-two week high of $25.17. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 0.98. The stock’s fifty day moving average is $17.16 and its two-hundred day moving average is $18.04. The firm has a market capitalization of $33.36 billion, a P/E ratio of 23.21 and a beta of 0.60.

Kenvue (NYSE:KVUE) last issued its earnings results on Monday, November 3rd. The company reported $0.28 EPS for the quarter, beating analysts’ consensus estimates of $0.27 by $0.01. The business had revenue of $3.76 billion during the quarter, compared to analysts’ expectations of $3.83 billion. Kenvue had a net margin of 9.55% and a return on equity of 20.02%. The company’s quarterly revenue was down 3.5% compared to the same quarter last year. During the same period in the prior year, the business earned $0.28 earnings per share. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. Research analysts expect that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, February 25th. Shareholders of record on Wednesday, February 11th will be paid a $0.2075 dividend. This represents a $0.83 dividend on an annualized basis and a yield of 4.8%. The ex-dividend date of this dividend is Wednesday, February 11th. Kenvue’s dividend payout ratio (DPR) is 110.67%.

Wall Street Analysts Forecast Growth

Several analysts have commented on KVUE shares. JPMorgan Chase & Co. dropped their price objective on Kenvue from $24.00 to $21.00 and set an “overweight” rating on the stock in a report on Friday, October 10th. Citigroup decreased their target price on Kenvue from $20.00 to $17.00 and set a “neutral” rating on the stock in a research report on Thursday, October 9th. Zacks Research raised shares of Kenvue from a “strong sell” rating to a “hold” rating in a report on Wednesday, November 26th. Deutsche Bank Aktiengesellschaft set a $18.00 price objective on shares of Kenvue in a research report on Friday, October 24th. Finally, Evercore ISI set a $18.00 target price on shares of Kenvue in a research report on Tuesday, October 28th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and thirteen have assigned a Hold rating to the company’s stock. According to MarketBeat.com, Kenvue currently has a consensus rating of “Hold” and a consensus price target of $19.90.

Insider Buying and Selling at Kenvue

In related news, Director Jeffrey C. Smith purchased 3,200,000 shares of the company’s stock in a transaction dated Friday, December 12th. The stock was acquired at an average cost of $17.37 per share, for a total transaction of $55,584,000.00. Following the completion of the transaction, the director directly owned 27,307,632 shares of the company’s stock, valued at approximately $474,333,567.84. This trade represents a 13.27% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 1.68% of the stock is currently owned by corporate insiders.

About Kenvue

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over?the?counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.